Anne Pariser

1.9k total citations · 1 hit paper
35 papers, 782 citations indexed

About

Anne Pariser is a scholar working on Genetics, Molecular Biology and Economics and Econometrics. According to data from OpenAlex, Anne Pariser has authored 35 papers receiving a total of 782 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Genetics, 15 papers in Molecular Biology and 10 papers in Economics and Econometrics. Recurrent topics in Anne Pariser's work include Genomics and Rare Diseases (16 papers), CRISPR and Genetic Engineering (8 papers) and Health Systems, Economic Evaluations, Quality of Life (7 papers). Anne Pariser is often cited by papers focused on Genomics and Rare Diseases (16 papers), CRISPR and Genetic Engineering (8 papers) and Health Systems, Economic Evaluations, Quality of Life (7 papers). Anne Pariser collaborates with scholars based in United States, Canada and Australia. Anne Pariser's co-authors include Petra Kaufmann, Christopher P. Austin, Amy S. Rosenberg, Daniela Verthelyi, Inna Cintina, Susan Kirshner, Jinhai Wang, Gibbes R. Johnson, Annie Kennedy and Elisabeth Oehrlein and has published in prestigious journals such as Nature Biotechnology, Nature Reviews Drug Discovery and PEDIATRICS.

In The Last Decade

Anne Pariser

33 papers receiving 754 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The national economic burden of rare disease in the United States in 2019

2022 98 citations Inna Cintina, Anne Pariser et al. Orphanet Journal of Rare Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anne Pariser United States	17	229	215	154	137	83	35	782
Charlotte Rodwell France	5	551 2.4×	302 1.4×	52 0.3×	115 0.8×	59 0.7×	7	920
Stéphanie Nguengang Wakap France	4	494 2.2×	275 1.3×	47 0.3×	101 0.7×	52 0.6×	7	854
Yann Le Cam France	12	729 3.2×	400 1.9×	89 0.6×	265 1.9×	120 1.4×	25	1.4k
Annie Olry France	4	633 2.8×	438 2.0×	53 0.3×	107 0.8×	64 0.8×	8	1.1k
Elisabeth Dequeker Belgium	23	404 1.8×	458 2.1×	112 0.7×	38 0.3×	130 1.6×	76	1.7k
Ellen Copson United Kingdom	21	357 1.6×	430 2.0×	145 0.9×	26 0.2×	139 1.7×	71	1.5k
Linda S. Wood United States	20	129 0.6×	392 1.8×	46 0.3×	29 0.2×	46 0.6×	45	1.2k
Beat M. Frey Switzerland	19	180 0.8×	330 1.5×	231 1.5×	21 0.2×	104 1.3×	56	1.3k
Anne M. Noonan United States	27	185 0.8×	561 2.6×	77 0.5×	34 0.2×	75 0.9×	117	2.1k
Stephen M. Schleicher United States	19	48 0.2×	609 2.8×	59 0.4×	144 1.1×	78 0.9×	62	1.3k

Countries citing papers authored by Anne Pariser

Since Specialization

Citations

This map shows the geographic impact of Anne Pariser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Pariser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Pariser more than expected).

Fields of papers citing papers by Anne Pariser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Pariser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Pariser. The network helps show where Anne Pariser may publish in the future.

Co-authorship network of co-authors of Anne Pariser

This figure shows the co-authorship network connecting the top 25 collaborators of Anne Pariser. A scholar is included among the top collaborators of Anne Pariser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Pariser. Anne Pariser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chow, Shein‐Chung, et al.. (2025). Use of alternative and confirmatory data in support of rare disease drug development. Journal of Biopharmaceutical Statistics. 35(6). 1005–1019. 1 indexed citations

Chow, Shein‐Chung, et al.. (2025). The role of regulatory flexibility in the review and approval process of rare disease drug development. Journal of Biopharmaceutical Statistics. 35(6). 1020–1031.

Shchelochkov, Oleg A., Randy J. Chandler, Lina Li, et al.. (2025). Adeno-Associated Virus Gene Therapy Development: Early Planning and Regulatory Considerations to Advance the Platform Vector Gene Therapy Program. Human Gene Therapy. 36(5-6). 653–662. 1 indexed citations

Wang, Chiuhui Mary, Ana Rath, Diego Ardigò, et al.. (2024). Operational description of rare diseases: a reference to improve the recognition and visibility of rare diseases. Orphanet Journal of Rare Diseases. 19(1). 334–334. 6 indexed citations

Nabbout, Rima, Dixie B. Baker, Lora Black, et al.. (2023). Towards the international interoperability of clinical research networks for rare diseases: recommendations from the IRDiRC Task Force. Orphanet Journal of Rare Diseases. 18(1). 109–109. 4 indexed citations

Cintina, Inna, et al.. (2022). The national economic burden of rare disease in the United States in 2019. Orphanet Journal of Rare Diseases. 17(1). 163–163. 98 indexed citations breakdown →

Bax, Ralph, Andrea Gropman, Anne Pariser, et al.. (2022). Global Regulatory and Public Health Initiatives to Advance Pediatric Drug Development for Rare Diseases. Therapeutic Innovation & Regulatory Science. 56(6). 964–975. 16 indexed citations

Zhu, Qian, Ðắc-Trung Nguyễn, Timothy Sheils, et al.. (2021). Scientific evidence based rare disease research discovery with research funding data in knowledge graph. Orphanet Journal of Rare Diseases. 16(1). 483–483. 11 indexed citations

Cutillo, Christine M., Pierantonio Russo, Bryan Laraway, et al.. (2021). The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems. Orphanet Journal of Rare Diseases. 16(1). 429–429. 53 indexed citations

10.

Zhu, Qian, Ðắc-Trung Nguyễn, Ivan Grishagin, et al.. (2020). An integrative knowledge graph for rare diseases, derived from the Genetic and Rare Diseases Information Center (GARD). Journal of Biomedical Semantics. 11(1). 13–13. 26 indexed citations

11.

Zhu, Qian, et al.. (2020). Phenotypically Similar Rare Disease Identification from an Integrative Knowledge Graph for Data Harmonization: Preliminary Study. JMIR Medical Informatics. 8(10). e18395–e18395. 1 indexed citations

12.

Kaufmann, Petra, Anne Pariser, & Christopher P. Austin. (2018). From scientific discovery to treatments for rare diseases – the view from the National Center for Advancing Translational Sciences – Office of Rare Diseases Research. Orphanet Journal of Rare Diseases. 13(1). 196–196. 91 indexed citations

13.

Pariser, Anne, et al.. (2014). Pre—Investigational New Drug Meetings With the FDA: Evaluation of Meeting Content and Characteristics of Applications for New Drug and Biologic Products. Therapeutic Innovation & Regulatory Science. 49(3). 434–442. 2 indexed citations

14.

Liu, Ke, et al.. (2012). Rare Cancer Trial Design: Lessons from FDA Approvals. Clinical Cancer Research. 18(19). 5172–5178. 49 indexed citations

15.

Pariser, Anne, et al.. (2012). Characteristics of rare disease marketing applications associated with FDA product approvals 2006–2010. Drug Discovery Today. 17(15-16). 898–904. 13 indexed citations

16.

Lacaná, Emanuela, Lynne Yao, Anne Pariser, & Amy S. Rosenberg. (2012). The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease. American Journal of Medical Genetics Part C Seminars in Medical Genetics. 160C(1). 30–39. 18 indexed citations

17.

Pariser, Anne, et al.. (2012). Cross-sector sponsorship of research in eosinophilic esophagitis: A collaborative model for rational drug development in rare diseases. Journal of Allergy and Clinical Immunology. 130(3). 613–616. 25 indexed citations

18.

Coté, Timothy R., Kui Xu, & Anne Pariser. (2010). Accelerating orphan drug development. Nature Reviews Drug Discovery. 9(12). 901–902. 22 indexed citations

19.

Dickson, Patricia, Anne Pariser, Stephen C. Groft, et al.. (2010). Research challenges in central nervous system manifestations of inborn errors of metabolism. Molecular Genetics and Metabolism. 102(3). 326–338. 18 indexed citations

20.

Wang, Jinhai, Jay N. Lozier, Gibbes R. Johnson, et al.. (2008). Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nature Biotechnology. 26(8). 901–908. 130 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact